An ongoing phase 2, single-center, randomized placebo-controlled trial in adults with PAH including patients with PAH-CHD is evaluating the effects of famotidine in improving 6MWD, NYHA functional class, and decreasing BNP levels [76]. The gene discussed is NPPB; the disease is coronary artery disorder.